Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model
Authors:
- Elisabeth RossaertERElisabeth Rossaert
- Eveliina PollariEPEveliina Pollari
- Tom JaspersTJTom Jaspers
- Lawrence Van HelleputteLHLawrence Van Helleputte
- Matthew JarpeMJMatthew Jarpe
- Philip Van DammePDPhilip Van Damme
- Katrien De BockKBKatrien De Bock
- Matthieu MoisseMMMatthieu Moisse
- Ludo Van Den BoschLBLudo Van Den Bosch
Open Access
- 5 July 2019
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 7 (1) , 1-19
Abstract
Dysregulation of epigenetic mechanisms is emerging as a central event in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). In many models of neurodegeneration, global histone acetylation is decreased in the affected neuronal tissues. Histone acetylation is controlled by the antagonistic actions of two protein families –the histone acetyltransferases (HATs) and the histone deacetylases (HDACs). Drugs inhibiting HDAC activity are already used in the clinic as anti-cancer agents. The aim of this study was to explore the therapeutic potential of HDAC inhibition in the context of ALS. We discovered that transgenic mice overexpressing wild-type FUS (“Tg FUS+/+”), which recapitulate many aspects of human ALS, showed reduced global histone acetylation and alterations in metabolic gene expression, resulting in a dysregulated metabolic homeostasis. Chronic treatment of Tg FUS+/+ mice with ACY-738, a potent HDAC inhibitor that can cross the blood-brain barrier, ameliorated the motor phenotype and substantially extended the life span of the Tg FUS+/+ mice. At the molecular level, ACY-738 restored global histone acetylation and metabolic gene expression, thereby re-establishing metabolite levels in the spinal cord. Taken together, our findings link epigenetic alterations to metabolic dysregulation in ALS pathology, and highlight ACY-738 as a potential therapeutic strategy to treat this devastating disease.Keywords
Funding Information
- Fund for Scientific Research Flanders (G.0431.12N and G.0440.12N)
- Interuniversity Attraction Poles Programme (P7/16)
- Muscular Dystrophy Association (577668)
- als liga
- European Community's Health Seventh Framework Programme (FP7/2007-2013)
- ALS Therapy Alliance
- Amyotrophic Lateral Sclerosis Association (14-LGCA-181)
- Fondation Thierry Latran
- Opening the Future - KU Leuven
- Fonds Wetenschappelijk Onderzoek
- Een Hart voor ALS
- Laevers fund for ALS research
- Agentschap voor Innovatie door Wetenschap en Technologie
- Saastamoinen Foundation
- Instrumentarium Science Foundation
- Finnish Cultural Foundation
This publication has 80 references indexed in Scilit:
- Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative diseaseTranslational Research, 2019
- A novel role for central ACBP/DBI as a regulator of long‐chain fatty acid metabolism in astrocytesJournal of Neurochemistry, 2015
- Activity-dependent FUS dysregulation disrupts synaptic homeostasisProceedings of the National Academy of Sciences, 2014
- Mutations in the 3′ untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosisHuman Molecular Genetics, 2013
- Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashionActa Neuropathologica, 2012
- The genetics and neuropathology of amyotrophic lateral sclerosisActa Neuropathologica, 2012
- Neuronal LRP1 Knockout in Adult Mice Leads to Impaired Brain Lipid Metabolism and Progressive, Age-Dependent Synapse Loss and NeurodegenerationThe Journal of Neuroscience, 2010
- Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcriptionNature, 2008
- Histone acetylation: a switch between repressive and permissive chromatinEMBO Reports, 2002
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994